RE:RE:Patients have already been treated.floatinketucky wrote: "Theralase is currently working to register up to an additional 19 clinical study sites this year"
With that statement in the PR I expect the June phone call to the FDA has already happened and it was encouraging enough for the company to release a nice new timeline guidance.
in order to have 19 clinical study sites registered this year simply means the FDA Phase 2 study submission is very near term.
The company is currently treating paitients. I'm considering a update is also very near term.
Our process in about to get the first production scale up, the market will notice. JMO
I'm not concerned about the funding at all. The company is not either.
Prospectus Withdrawn on May 16, 2019
OSC NOTICE TO PUBLIC
ISSUER: Theralase Technologies Inc. Principal Jurisdiction - Ontario
DATES: Preliminary Shelf Prospectus (NI 44-102) dated April 26, 2019 Withdrawn on May 16, 2019
PROJECT NUMBER: 2906418
JMO Exciting times here,
This is looking really good!
The company has not stated it is currently treating patients in the phase 2 trial nor that it has had a phone discussion with the FDA. That is only your assumption derived from reading the tea leaves.